Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Loos

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Clinical Pharmacology and Therapeutics|May 24, 2012
Effects of CYP induction by rifampicin on tamoxifen exposureL Binkhorst, T van Gelder, W J Loos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumorsC J Gerrits, H Burris, J H Schellens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumorsM J de Jonge, C J Punt, A H Gelderblom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2006
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumorsJ A Gietema, R Hoekstra, F Y F L de Vos, et al.
Investigational New Drugs|May 11, 2002
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studiesJ H M Schellens, B Heinrich, M Lehnert, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Clinical Pharmacology and Therapeutics|May 24, 2012
Effects of CYP induction by rifampicin on tamoxifen exposureL Binkhorst, T van Gelder, W J Loos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 1998
Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumorsC J Gerrits, H Burris, J H Schellens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumorsM J de Jonge, C J Punt, A H Gelderblom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 27, 2006
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumorsJ A Gietema, R Hoekstra, F Y F L de Vos, et al.
Investigational New Drugs|May 11, 2002
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studiesJ H M Schellens, B Heinrich, M Lehnert, et al.
Pageof 7